RxDoctor Payments Data

Syeda Khan, MD

Internal Medicine · Tampa, FLNPI 1366639221

Payments from drug & device makers

$1,977in general payments, 2019–2025

Across 100 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$355
  • Lilly USA, LLC$308
  • AstraZeneca$259
  • Pfizer$139
  • Sight Sciences, Inc.$125
  • AbbVie$124
  • plus $667 from 13 others

What the payments were for

  • Food & beverage$1,977100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,977 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$110,668
Medicare patients
398
Services billed
1,504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$118,364
MounjaroTirzepatide88$110,265
EliquisApixaban96$86,088
JardianceEmpagliflozin63$80,350
TrulicityDulaglutide43$62,162
FarxigaDapagliflozin Propanediol34$43,890
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$30,857
JanuviaSitagliptin Phosphate19$24,154
XareltoRivaroxaban25$23,721
RybelsusSemaglutide15$21,825
LinzessLinaclotide15$20,406
SymbicortBudesonide/Formoterol Fumarate23$5,547
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$5,467
Sucralfate14$5,376
Novolog FlexpenInsulin Aspart16$5,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$308$172,428131 claims
Novo NordiskOzempic, Rybelsus$355$140,189115 claims
PfizerEliquis$139$86,08896 claims
Boehringer IngelheimJardiance$114$80,35063 claims
AstraZenecaFarxiga, Symbicort$259$49,43857 claims
AbbVieLinzess, Synthroid$124$21,83834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →